Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DAB2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DAB2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DAB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DAB2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DAB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009013019 | Oral cavity | EOLP | tissue migration | 80/2218 | 365/18723 | 2.89e-08 | 1.16e-06 | 80 |
GO:000726522 | Oral cavity | EOLP | Ras protein signal transduction | 74/2218 | 337/18723 | 8.76e-08 | 3.09e-06 | 74 |
GO:009719125 | Oral cavity | EOLP | extrinsic apoptotic signaling pathway | 54/2218 | 219/18723 | 9.74e-08 | 3.36e-06 | 54 |
GO:003596724 | Oral cavity | EOLP | cellular response to topologically incorrect protein | 35/2218 | 116/18723 | 9.93e-08 | 3.40e-06 | 35 |
GO:000222113 | Oral cavity | EOLP | pattern recognition receptor signaling pathway | 45/2218 | 172/18723 | 1.82e-07 | 5.82e-06 | 45 |
GO:007135623 | Oral cavity | EOLP | cellular response to tumor necrosis factor | 55/2218 | 229/18723 | 1.90e-07 | 6.02e-06 | 55 |
GO:004312223 | Oral cavity | EOLP | regulation of I-kappaB kinase/NF-kappaB signaling | 58/2218 | 249/18723 | 2.72e-07 | 8.22e-06 | 58 |
GO:003462024 | Oral cavity | EOLP | cellular response to unfolded protein | 30/2218 | 96/18723 | 3.43e-07 | 1.01e-05 | 30 |
GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
GO:003461224 | Oral cavity | EOLP | response to tumor necrosis factor | 58/2218 | 253/18723 | 4.79e-07 | 1.32e-05 | 58 |
GO:007190023 | Oral cavity | EOLP | regulation of protein serine/threonine kinase activity | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
GO:003134621 | Oral cavity | EOLP | positive regulation of cell projection organization | 74/2218 | 353/18723 | 6.00e-07 | 1.56e-05 | 74 |
GO:000724924 | Oral cavity | EOLP | I-kappaB kinase/NF-kappaB signaling | 62/2218 | 281/18723 | 8.00e-07 | 2.02e-05 | 62 |
GO:004573226 | Oral cavity | EOLP | positive regulation of protein catabolic process | 53/2218 | 231/18723 | 1.43e-06 | 3.42e-05 | 53 |
GO:001635815 | Oral cavity | EOLP | dendrite development | 55/2218 | 243/18723 | 1.43e-06 | 3.42e-05 | 55 |
GO:001097515 | Oral cavity | EOLP | regulation of neuron projection development | 86/2218 | 445/18723 | 2.75e-06 | 6.05e-05 | 86 |
GO:001063219 | Oral cavity | EOLP | regulation of epithelial cell migration | 62/2218 | 292/18723 | 3.09e-06 | 6.74e-05 | 62 |
GO:003011123 | Oral cavity | EOLP | regulation of Wnt signaling pathway | 67/2218 | 328/18723 | 5.11e-06 | 1.04e-04 | 67 |
GO:006113626 | Oral cavity | EOLP | regulation of proteasomal protein catabolic process | 44/2218 | 187/18723 | 5.44e-06 | 1.08e-04 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DAB2 | SNV | Missense_Mutation | | c.1639N>A | p.Gly547Ser | p.G547S | P98082 | protein_coding | tolerated(0.28) | benign(0.043) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DAB2 | SNV | Missense_Mutation | rs376782436 | c.1729G>A | p.Ala577Thr | p.A577T | P98082 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DAB2 | SNV | Missense_Mutation | novel | c.1797N>A | p.Phe599Leu | p.F599L | P98082 | protein_coding | deleterious(0.03) | possibly_damaging(0.459) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DAB2 | SNV | Missense_Mutation | | c.5C>T | p.Ser2Phe | p.S2F | P98082 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DAB2 | SNV | Missense_Mutation | | c.796N>G | p.Pro266Ala | p.P266A | P98082 | protein_coding | deleterious(0.05) | possibly_damaging(0.62) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DAB2 | SNV | Missense_Mutation | | c.2277N>C | p.Glu759Asp | p.E759D | P98082 | protein_coding | tolerated(1) | benign(0) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DAB2 | SNV | Missense_Mutation | novel | c.1546N>G | p.Thr516Ala | p.T516A | P98082 | protein_coding | tolerated(0.93) | benign(0) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DAB2 | SNV | Missense_Mutation | novel | c.1931N>T | p.Gly644Val | p.G644V | P98082 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-E9-A3HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
DAB2 | insertion | Nonsense_Mutation | novel | c.1317_1318insTGACTCTTTTGCTTTTGCTCATAAAATGATGATGCATC | p.Gly440Ter | p.G440* | P98082 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DAB2 | insertion | Nonsense_Mutation | novel | c.1581_1582insACTTTGATGCTAATCAACTATTGA | p.Met527_Ala528insThrLeuMetLeuIleAsnTyrTer | p.M527_A528insTLMLINY* | P98082 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |